SpyGlass Pharma, Inc. SGP
36.95 USD +2.87 (+8.41%)
At closeNov 6, 2026, 4:00 PM EST
36.95 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
33.93 Day range 37.12
17.06 52-week range 37.12
- YTD
- +39.94%
- 1 year
- +39.94%
- Market cap
- 1.24B
- EPS (ttm)
- -2.51
- Shares out
- 33.45M
- Forward P/E
- -13.13
- YTD return
- +39.94%
- 1-year return
- +39.94%
- Volume
- 109.37K
- Avg volume
- 107.52K
- Open
- 34.50
- Previous close
- 34.08
- Day's range
- 33.93 – 37.12
- 52-week range
- 17.06 – 37.12
- Analysts
- Strong Buy
- Price target
- 44.00 (+19.1%)
- Earnings date
- Nov 5, 2026
ALL +10.54 (+39.92%)
Key statistics
- Enterprise value
- 907.35M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 234.19M
- Total debt
- 1.63M
- Return on equity
- 0.00%
- Short % of float
- 11.03%
- 50-day average
- 27.84
- 200-day average
- 24.57
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 44.00 +19.1% upside
Now 36.95
- Target (low)
- 37.00
- Target (mean)
- 44.00
- Target (high)
- 62.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.62247.
Financials — quick view
SGP Revenue — quarterly 0
SGP Net income — quarterly -19.86M
SGP EPS — quarterly -0.59
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.62247 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.51442 | -0.59 | -0.08 | -14.69% |
| May 15, 2026 | Mar 31, 2026 | -0.67 | -0.69 | -0.02 | -2.99% |
| Mar 26, 2026 | Dec 31, 2025 | -0.57422 | -5.72 | -5.15 | -896.13% |
| Dec 3, 2025 | Sep 30, 2025 | — | -0.44776 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Raymond James | init | — | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | init | — | Buy |
| Mar 3, 2026 | Citigroup | init | — | Buy |
| Mar 3, 2026 | Leerink Partners | init | — | Outperform |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyglasspharma.com
News
SpyGlass Pharma to Participate in Upcoming Investor Conferences 
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target 
SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops 
HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target 
SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash 
This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED) 
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39 
SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant 
SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate - SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY
Your note
Sign in to keep a note on SGP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
| BEHBAHANI ALI | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
| MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.99% | 8,021,117 | 296.34M | Jun 29, 2026 |
| NEA Management Company, LLC | 22.11% | 7,392,301 | 273.11M | Jun 29, 2026 |
| Sands Capital Alternatives, LLC | 7.48% | 2,500,012 | 92.36M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 6.31% | 2,109,953 | 77.95M | Jun 29, 2026 |
| Blackrock Inc. | 2.13% | 711,712 | 26.29M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.02% | 674,143 | 24.91M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.95% | 317,053 | 11.71M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.87% | 291,272 | 10.76M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.74% | 247,196 | 9.13M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.73% | 245,044 | 9.05M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.69% | 229,706 | 8.49M | Jun 29, 2026 |
| abrdn Healthcare Investors | 0.64% | 214,473 | 7.92M | Jun 29, 2026 |